Use of brand names
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Editor, – Julian Fidge's letter ('Letters' Aust Prescr 1997;20:84) suggests that medical students should not have to learn brand names of drugs as they are 'pointless' in a teaching environment. To a certain extent, this is true as he will certainly be expected to prescribe by generic names when he graduates. However, the patients that he admits or sees in the Emergency Service and Outpatients Department will almost certainly refer to their drugs by brand names. Ignorance of the more common brand names will make life difficult for all concerned. I submit that the proper approach is to refer to the drugs by their generic names, but also to ensure that the more common brand names are also mentioned. In this way, all possible bases are covered.